Green Cross Health (NZSE:GXH) Research & Development: NZ$0.0 Mil (TTM As of Mar. 2026)


NZSE:GXH Green Cross Health Ltd NZSE:GXH
63 GF Score
Price NZ$2.00
GF Value NZ$1.08
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Green Cross Health Research & Development?

Green Cross Health NZSE:GXH +1.01% 63 Research & Development is NZ$0.0 Mil as of Mar. 2026. GuruFocus rates NZSE:GXH with a GF Score™ of 63/100 and a GF Value™ of NZ$1.08 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Green Cross Health's Research & Development for the six months ended in Mar. 2026 was NZ$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$0.0 Mil.

Green Cross Health  (NZSE:GXH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Green Cross Health Research & Development Related Terms

Green Cross Health Research & Development Historical Data

* Premium members only.

The historical data trend for Green Cross Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Green Cross Health Research & Development Chart

Green Cross Health Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Green Cross Health Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NZSE:GXH
63GF Score
Green Cross Health Ltd NZSE:GXH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Green Cross Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NZ$0.0 Mil mean?
Green Cross Health (NZSE:GXH) has a Research & Development of NZ$0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Green Cross Health and its competitors.
Is Green Cross Health's Research & Development too high?
Green Cross Health's current Research & Development is NZ$0.0 Mil. Overall, Green Cross Health has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Green Cross Health's Research & Development compare to competitors?
Green Cross Health's Research & Development of NZ$0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Green Cross Health and its competitors. Green Cross Health's current Research & Development is NZ$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Cross Health stock overvalued right now?
Based on GuruFocus' analysis, Green Cross Health (NZSE:GXH) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$1.08, compared to a current price of NZ$2.00 — trading 85.2% above its estimated fair value. The current Research & Development is NZ$0.0 Mil. Green Cross Health's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Green Cross Health (NZSE:GXH), the current Research & Development is NZ$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Green Cross Health (NZSE:GXH) Overvalued in 2026?

Based on GuruFocus' analysis, Green Cross Health stock appears to be overvalued. The current stock price of NZ$2.00 is trading 85.2% above its estimated GF Value™ of NZ$1.08. GuruFocus considers Green Cross Health to be Significantly Overvalued.

Key valuation signals for NZSE:GXH:

  • Research & Development: NZ$0.0 Mil
  • GF Value™: NZ$1.08 vs. price of NZ$2.00 (85.2% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the NZSE:GXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Green Cross Health Business Description

Address 602 Great South Road, Ellerslie, Ground Floor, Building B, Millennium Centre, Auckland, NTL, NZL, 1051
Green Cross Health Ltd is engaged in providing healthcare services in New Zealand. The reportable segments of the group are Pharmacy services and medical services. The majority of the revenue is generated from the Pharmacy services segment. The pharmacy services segment provides retail and dispensary services, and the medical services segment provides GP, nursing, and urgent care services. The majority of its revenue is generated from the pharmacy segment.
63GF Score

Get the complete analysis for NZSE:GXH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$2.00
Price
NZ$1.08
GF Value